Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.850028
Abstract: The pharmacodynamics of the purinergic receptor type Y, subtype 12 (P2Y12) inhibitors has evolved. Our understanding of the metabolism of P2Y12 inhibitors has revealed polymorphisms that impact drug metabolism and antiplatelet efficacy, leading to genetic… read more here.
Keywords: p2y12; review current; therapy; genotype guided ... See more keywords